May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Lesion Progression and Visual Acuity Outcomes for Occult Choroidal Neovascularization Treated With Rostaporfin (SnET2) Photodynamic Therapy
Author Affiliations & Notes
  • E.L. Thomas
    Retina–Vitreous Associates, Santa Monica, CA
  • R.P. Danis
    Univer. of Wisconsin, Madison, WI
  • SnET2 Study Group
    Retina–Vitreous Associates, Santa Monica, CA
  • Footnotes
    Commercial Relationships  E.L. Thomas, Miravant Pharmaceuticals. Inc. C; R.P. Danis, Miravant Pharmaceuticals. Inc. C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 3571. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E.L. Thomas, R.P. Danis, SnET2 Study Group; Lesion Progression and Visual Acuity Outcomes for Occult Choroidal Neovascularization Treated With Rostaporfin (SnET2) Photodynamic Therapy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):3571.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To present 2–year angiographic and visual acuity outcomes for patients with occult choroidal neovascularization (CNV) treated with rostaporfin (SnET2, or Photrexï£&#170;) photodynamic therapy (PDT). Methods: Two identical randomized, multicenter, double–masked, placebo–controlled trials compared intravenous rostaporfin 0.5 mg/kg with placebo (vehicle) for treatment of subfoveal CNV secondary to AMD (n=927). Eligible patients were < 50 years of age with a diagnosis of CNV consistent with AMD, an active subfoveal CNV lesion containing some classic component < 3.0 mm and best–corrected visual acuity of 15–60 ETDRS letters. Patients were re–treated with at intervals of no less than 13 weeks, with 1 retreatment required as a minimal exposure to the treatment. The primary endpoint was the proportion of patients losing 50% occult lesions (Predominantly Occult). Results: Pure Occult Analysis of both populations showed a benefit for rostaporfin in proportion of patients losing <15 letters from baseline. Statistically significant differences were seen for the PP Pure Occult population in the primary outcome (65.4% vs 0%; P<0.001) and secondary visual acuity outcomes: mean VA change and < 30 letters lost. The PP Pure Occult lesions treated with rostaporfin remained stable during the 2 year study period, while the lesions in the placebo group continued to grow throughout the study period. Predominantly Occult Predominantly Occult lesions similarly benefited from rostaporfin treatment. Statistically significant differences in the proportion of patients losing < 15 letters (63.6% versus 29.4%; P= 0.01) and mean change in VA were seen in PP Predominantly Occult lesions. Reduction in all secondary angiographic parameters was seen, consistent with the effect in Pure Occult lesions. Conclusions: Rostaporfin PDT was effective in preserving visual acuity in patients with occult CNV lesions and effectively slowed the progression of occult CNV membranes.

Keywords: photodynamic therapy • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled • age-related macular degeneration 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.